Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (Nasdaq: CRDF) announced positive findings from its Phase 2 trial of onvansertib for metastatic castration-resistant prostate cancer (mCRPC) at the 27th Annual PCF Scientific Retreat. The trial showed that 31% of evaluable patients achieved disease control after 12 weeks, with a durable response noted in several cases. A gene signature biomarker was identified to predict patient response to the drug in combination with Zytiga® (abiraterone). Safety data indicated no significant issues across varying doses, reinforcing the potential of onvansertib to address drug resistance in mCRPC.

Cardiff Oncology, Inc. (Nasdaq: CRDF) has priced its underwritten public offering of 6,500,000 shares of common stock at $13.50 per share, aiming to raise approximately $88 million in gross proceeds. The offering is anticipated to close on or around October 2, 2020, pending customary conditions. Proceeds will be utilized for the clinical development of their drug candidate, onvansertib, alongside working capital and general corporate needs. Underwriters have a 30-day option to acquire an additional 975,000 shares at the offering price.

Cardiff Oncology (Nasdaq: CRDF) has initiated an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to buy up to an additional 15% of shares sold. Proceeds from the offering will be directed towards the clinical development of onvansertib, working capital, and other corporate purposes. The offering is governed by a shelf registration statement effective from July 1, 2019. Cowen and Piper Sandler & Co. serve as joint book-running managers for this offering.

Cardiff Oncology (Nasdaq: CRDF) announced promising clinical data for onvansertib, a potential treatment for KRAS-mutated metastatic colorectal cancer (mCRC), presented at the ESMO Virtual Congress 2020. The trial showed that 91% of patients achieved disease control, with 45% attaining partial responses. Additionally, 73% exhibited durable responses lasting over six months. The study indicates that decreases in plasma KRAS mutation levels may predict tumor shrinkage. Onvansertib was well tolerated with no serious adverse effects reported, highlighting its potential as a second-line therapy for mCRC patients.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced a key opinion leader (KOL) call on Sept. 23, 2020, to discuss KRAS-mutated colorectal cancer and provide insights from its onvansertib Phase 1b/2 clinical trial. The call will feature presentations from CEO Dr. Mark Erlander and prominent oncologists, emphasizing clinical trial data and the role of KRAS as a biomarker for patient selection. Onvansertib, a PLK1 inhibitor, is being evaluated alongside standard treatments for metastatic colorectal cancer. The event aims to enhance understanding of treatment options and patient outcomes.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the publication of an abstract for an electronic poster at the ESMO Virtual Congress 2020. This abstract presents preliminary clinical data from an ongoing Phase 1b/2 trial of onvansertib, combined with FOLFIRI and bevacizumab, for treating KRAS-mutated metastatic colorectal cancer. Findings indicate the treatment's safety and efficacy, with changes in plasma KRAS mutation levels predicting clinical response. The presentation is scheduled for September 17, 2020, with details available on Cardiff Oncology's website.

Cardiff Oncology (Nasdaq: CRDF) announced significant advancements in its clinical programs and financial results for Q2 2020. The company demonstrated promising efficacy and safety of onvansertib for KRAS-mutated colorectal cancer and acute myeloid leukemia, achieving notable clinical milestones. Securing financing of $25 million bolstered its operations and clinical trials. The FDA granted Fast Track Designation for onvansertib in colorectal cancer, enhancing its development prospects. Cardiff's operating expenses decreased, reflecting effective cost management.

Cardiff Oncology (Nasdaq: CRDF) announced participation in the BTIG Biotechnology Virtual Conference on August 10-11, 2020. CEO Dr. Mark Erlander will discuss the advancements and challenges in KRAS inhibition for solid tumors, highlighting onvansertib, a first-in-class Polo-like Kinase 1 (PLK1) inhibitor. The discussion aims to address the potential of onvansertib in treating KRAS-mutated colorectal cancer, a historically challenging area. Attendees can join the presentation through the conference portal.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology company, announced participation in the William Blair Biotech Focus Conference from August 4-6. CEO Dr. Mark Erlander will conduct a fireside chat on August 6 at 10:00 a.m. PT, discussing their investigational drug onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor, currently in trials for KRAS-mutated colorectal cancer, castration-resistant prostate cancer, and leukemia. The webcast can be accessed via Cardiff's website and will be archived for 90 days.